Supplement

You have full text access to this OnlineOpen article

Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: Overview of methods†‡§

  1. Meg Watson MPH1,¶,*,
  2. Mona Saraiya MD, MPH1,
  3. Faruque Ahmed MD, PhD2,
  4. Cheryll J. Cardinez MD, MSPH1,
  5. Marsha E. Reichman PhD3,
  6. Hannah K. Weir PhD1,
  7. Thomas B. Richards MD1

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23758

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 2841–2854, 15 November 2008

Additional Information

How to Cite

Watson, M., Saraiya, M., Ahmed, F., Cardinez, C. J., Reichman, M. E., Weir, H. K. and Richards, T. B. (2008), Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: Overview of methods. Cancer, 113: 2841–2854. doi: 10.1002/cncr.23758

Author Information

  1. 1

    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

  2. 2

    Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia

  3. 3

    Division of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland

  1. Fax: (770) 488-4639.

*Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, MS-K55, Atlanta, GA 30341

  1. †

    The maps in Figure ‖ were developed by James Cucinelli (IMS, Inc.) and Dave Stinchcomb (National Cancer Institute) based on the micromaps design (Carr and Pierson, 1996). Fonda Martin provided additional graphics assistance.

  2. ‡

    The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  3. §

    This is a US government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 7 MAY 2008
  4. Manuscript Revised: 6 MAY 2008
  5. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention (CDC)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (474K)

REFERENCES

  • 1
    Walboomers JMM,Jacobs MV,Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–19.
    Direct Link:
  • 2
    Parkin DM,Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S11–S25.
  • 3
    Kreimer AR,Clifford GM,Boyle P,Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14: 467–475.
  • 4
    Joura EA,Leodolter S,Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of 3 randomised clinical trials. Lancet. 2007; 369: 1693–1702.
  • 5
    Villa LL,Costa RL,Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95: 1459–1466.
  • 6
    National Institutes of Health. ClinicalTrials.gov. Bethesda, Md: National Institutes of Health, National Library of Medicine, Department of Health and Human Services; 2008. Available at: http://clinicaltrials.gov. Accessed January 7, 2008.
  • 7
    US Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence and Mortality. Atlanta, Ga: Centers for Disease Control and Prevention; 2005. Available at: http://www.cdc.gov/cancer/npcr/uscs/. Accessed October 23, 2007.
  • 8
    Hankey BF,Ries L,Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8: 1117–1121.
  • 9
    Thoburn KK,German RR,Lewis M,Nichols PJ,Ahmed F,Jackson-Thompson J. Case completeness and data accuracy in the Centers for Disease Control and Prevention's National Program of Cancer Registries. Cancer. 2007; 109: 1607–1616.
    Direct Link:
  • 10
    US Congress.Cancer Registries Amendment Act, Public Law No. 102-515, Stat. 3312. Congressional Record, 1992, volume 128. Washington, DC: US Department of Health and Human Services, Public Health Service; 1992.
  • 11
    Wingo PA,Jamison PM,Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control-a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003; 14: 175–193.
  • 12
    Surveillance, Epidemiology, and End Results (SEER) Program. The SEER Program Coding and Staging Manual 2004, Revision 1. NIH Publication No. 04-5581. Bethesda, Md: National Cancer Institute; 2007.
  • 13
    International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 14
    International Classification of Diseases for Oncology, 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
  • 15
    US Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence and Mortality. Atlanta, Ga: Centers for Disease Control and Prevention; 2006. Available at: http://www.cdc.gov/cancer/npcr/uscs/. Accessed October 23, 2007.
  • 16
    National Cancer Institute. Conversion Programs, ICD-O-2 to 3 and ICD-O-3 to 2. Bethesda, Md: Surveillance, Epidemiology, and End Results (SEER) Program; 2004. Available at: http://seer.cancer.gov/tools/conversion/. Accessed October 11, 2007.
  • 17
    National Cancer Registrars Association (NCRA). Central Cancer Registries: Design, Management and Use, 2nd ed. Dubuque, Iowa: Kendall/Hunt Publishing Company; 2007.
  • 18
    National Center for Health Statistics (NCHS). National Vital Statistics System. Atlanta, Ga: Centers for Disease Control and Prevention, National Center for Health Statistics; 2007. Available at: http://www.cdc.gov/nchs/nvss.htm. Accessed October 23, 2007.
  • 19
    National Cancer Institute. SEER Cause of Death Recode. Bethesda, Md: National Cancer Institute, Surveillance, Epidemiology, and End Results Program; 2008. Available at: http://seer.cancer.gov/codrecode/. Accessed February 8, 2008.
  • 20
    National Center for Health Statistics (NCHS). 2003 Revision of the US Standard Certificate of Death. Atlanta, Ga: NCHS; 2003. Available at: http://www.cdc.gov/nchs/data/dvs/DEATH11-03final-acc.pdf. Accessed March 25, 2008.
  • 21
    HavenerL, ed. Standards for Cancer Registries, Vol III: Standards for Completeness, Quality, Analysis, and Management of Data. Springfield, Ill: North American Association of Central Cancer Registries; 2004.
  • 22
    National Cancer Institute. SEER Data, 1973-2004. Bethesda, Md: National Cancer Institute; 2008. Available at: http://seer.cancer.gov/publicdata/. Accessed March 25, 2008.
  • 23
    NAACCR Latino Research Work Group. NAACCR guideline for enhancing Hispanic-Latino identification: revised NAACCR Hispanic/Latino identification algorithm (NHIA version 2). Springfield, Ill: North American Association of Central Cancer Registries; 2005.
  • 24
    Espey DK,Wu X,Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007; 110: 2119–2152.
    Direct Link:
  • 25
    National Center for Health Statistics (NCHS). Deaths: FinalData for 2003. Atlanta, Ga: NCHS; 2007. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/finaldeaths03/finaldeaths03.htm#1. Accessed March 25, 2008.
  • 26
    Surveillance Epidemiology and End Results. US Population Data-1969-2005. Bethesda, Md: National Cancer Institute; 2008. Available at: http://seer.cancer.gov/popdata/. Accessed March 25, 2008.
  • 27
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007; 90: 1–636.
  • 28
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 3030–3044.
    Direct Link:
  • 29
    Ryerson AB,Peters ES,Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the United States, 1998-2003. Cancer. 2008; 113( 10 suppl); 2901–2909.
    Direct Link:
  • 30
    Berg JW. Morphologic classification of human cancer. In: SchottenfeldD,FraumeniJF, eds. Cancer Epidemiology and Prevention,2nd ed. New York, NY: Oxford University Press; 1996: 28–44.
  • 31
    Saraiya M,Goodman MT,Datta SD,Chen VW,Wingo PA. Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role [commentary]. Cancer. 2008; 113( 10 suppl); 3047–3057.
    Direct Link:
  • 32
    Hampl M,Sarajuuri H,Wetzensen N,Bender HG,Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol. 2006; 108: 1361–1368.
  • 33
    Frisch M,Glimelius B,van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997; 337: 1350–1358.
  • 34
    Frisch M. On the etiology of anal squamous carcinoma. Danish Med Bull. 2002; 49: 194–209.
  • 35
    Melbye M,Frisch M. The role of human papillomaviruses in anogenital cancers. Semin Cancer Biol. 1998; 8: 307–313.
  • 36
    Joseph DA,Miller JW,Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the United States. Cancer. 2008; 113( 10 suppl); 2892–2900.
    Direct Link:
  • 37
    Kong C,Welton ML,Longacre T. Role of human papillomavirus in squamous cell metaplasia-dysplasia-carcinoma of the rectum. Am J Surg Pathol. 2007; 31: 919–925.
  • 38
    Johnson LG,Madeleine MM,Newcomer LM,Schwartz SM,Daling JR. Anal cancer incidence and survival: the Surveillance, Epidemiology, and End Results experience, 1973-2000. Cancer. 2004; 101: 281–288.
    Direct Link:
  • 39
    Surveillance Epidemiology, and End Results Program. 2000 US Standard Population vs Standard Million. Bethesda, Md: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/stdpopulations/single_age.html. Accessed October 23, 2007.
  • 40
    Surveillance Research Program, National Cancer Institute. SEER*Stat Software. Bethesda, Md: Surveillance Research Program, National Cancer Institute; 2007. Available at: http://seer.cancer.gov/seerstat/. Accessed March 25, 2008.
  • 41
    Tiwari RC,Clegg LX,Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006; 15: 547–569.
  • 42
    Howe HL,Jamison M,Havener L,Chen VW,Ries L. Site-specific comparison of Summary Stage 1977 and Summary Stage 2000 coding. Springfield, Ill: North America Association of Central Cancer Registries; 2007. Available at: http://www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=397 Accessed on March 25, 2008.
  • 43
    Phillips J. Summary Stage: Data Effects of the Changes in 2000. Springfield, Ill: North American Association of Central Cancer Registries; 2003.
  • 44
    Wu X,Matanoski G,Chen VW, et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer. 2008; 113( 10 suppl): 2873–2882.
    Direct Link:
  • 45
    Watson M,Saraiya M,Benard V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer. 2008; 113( 10 suppl): 2855–2864.
    Direct Link:
  • 46
    Saraiya M,Watson M,Wu X, et al. Incidence of in situ and invasive vulvar cancer in the United States, 1998-2003. Cancer. 2008; 113( 10 suppl): 2865–2872.
    Direct Link:
  • 47
    Hernandez BY,Barnholtz-Sloan J,German RR, et al. Burden of penile cancer in the United States. Cancer. 2008; 113( 10 suppl): 2883–2891.
    Direct Link:
  • 48
    National Program of Cancer Registries, Centers for Disease Control and Prevention. Ten Years of Progress: The National Program of Cancer Registries: CDC's Progress in Building a National Cancer Surveillance Network. Atlanta, Ga: Centers for Disease Control and Prevention; 2007. Available at: http://www.cdc.gov/cancer/npcr/anniversary/progress.htm. Accessed March 25, 2008.
  • 49
    Munoz N,Bosch FX,Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 111: 278–285.
    Direct Link:
  • 50
    Daling JR,Madeleine MM,Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002; 84: 263–270.
  • 51
    Trimble CL,Hildesheim A,Brinton LA,Shah KV,Kurman RJ. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol. 1996; 87: 59–64.
  • 52
    Iwasawa A,Nieminen P,Lehtinen M,Paavonen J. Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction. Obstet Gynecol. 1997; 89: 81–84.
  • 53
    Rubin MA,Kleter B,Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol. 2001; 159: 1211–1218.
  • 54
    Daling JR,Madeleine MM,Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004; 101: 270–280.
    Direct Link:
  • 55
    Frisch M,Fenger C,Van den Brule AJC, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res. 1999; 59: 753–757.
View Full Article (HTML) Get PDF (474K)